Sosei Co., Ltd.

43 articles about Sosei Co., Ltd.

• 

  Lilly Plunks Down up to $731M in GPCR Pact with Sosei

  12/16/2022

  Lilly digs deeper into metabolic diseases via GPCR partnership with Sosei.
• 

  AbbVie Says Goodbye to Sosei’s Neurological-Focused Muscarinic Agonist Programs

  1/5/2021

  Sosei Group Corporation has announced it is regaining the worldwide rights to its muscarinic agonist programs after AbbVie said it is backing away from the program.
• 

  Genentech Strikes Three Separate Drug Discovery Deals With Small Companies

  7/16/2019

  In a deal-making spree, Genentech will team up with the small companies to take on various diseases, including multiple sclerosis.

• Cell Medica Appoints Julia P. Gregory as Non-Executive Director and Audit Chair

  6/13/2018

  Cell Medica today announced the appointment of Julia P. Gregory as a Non-Executive Director and Audit Chair of the Company’s Board of Directors.

• Sosei Announces Key Appointments Of Head Of Investor Relations And Corporate Communications And Group Financial Controller

  9/19/2017

• Sosei: First Subject Dosed In Phase1 Clinical Study Of Novel Selective Muscarinic M4 Agonist In Development To Treat Major Symptoms Of Alzheimer's Disease

  9/1/2017

• Sosei Takes Huge Stake And Option To Buy Ambitious MiNA In Deal Worth $534 Million

  5/3/2017

• Sosei Subsidiary Heptares To Receive $12 Million Milestone Payment From AstraZeneca PLC

  4/5/2017

• Sosei Release: Company Appoints Andrew Oakley As CFO

  1/19/2017

• Sosei Subsidiaries Heptares And Jitsubo To Develop Novel GPCR-Targeting Peptide Candidates For Severe Gastro-Intestinal Disorders

  11/10/2016

• Sosei Names a New CEO, Effective Immediately

  6/24/2016

• Sosei Appoints Peter Bains As COO And CEO-Elect

  3/22/2016

• Sosei Subsidiary Heptares Announces Positive Results From Phase 1b Clinical Trial With HTL9936, A First-In-Class Selective Muscarinic M1Receptor Agonist For Improving Cognition In Dementia And Schizophrenia

  2/10/2016

• Pfizer Inks $1.89 Billion Discovery Deal with Heptares, Takes $33 Million Stake in Sosei

  11/30/2015

• Sosei Subsidiary Heptares Announces Positive Outcome Of Phase 1a Study With First-Ever Selective Muscarinic M1 Receptor Agonist For Improving Cognition In Patients With Alzheimer's Disease

  6/17/2015

• Sosei Snags UK Biotech Firm Heptares for $400 Million

  2/23/2015

• BioAlliance Pharma Pursues the Development Plan of Its Loramyc® in Japan Through Its Partner Sosei

  3/12/2013

• BioAlliance Pharma: Progress in the Development of Loramyc(R) in Japan Towards its Registration by the Partner Sosei Co., Ltd.

  7/2/2012

• BioAlliance Pharma Expands its Loramyc(R) Franchise in Japan With Sosei Co., Ltd. in a Deal Valued up to 18.5M$

  5/11/2011

• BioAlliance Expands its Loramyc(R) Franchise in Japan with Sosei Co., Ltd. in a Deal Valued up to $18.5 Million

  5/11/2011